This statistic shows the number of registrations of newly diagnosed cases of pancreatic cancer in England in 2022, by age group and gender. In this year, 902 cases of pancreatic cancer were reported among men aged 75 to 79 years. It should, of course, be noted that the number of people in England in each age group varies and is therefore not necessarily a reflection of susceptibility to pancreatic cancer.

In 2022, the rate of newly diagnosed pancreatic cancer cases in England was 20 per 100,000 for males and 16 per 100,000 for females. This represented a considerable increase in the rate of newly diagnosed cases for females compared to the previous year. This statistic shows the rate of newly diagnosed cases of pancreatic cancer per 100,000 population in England from 1995 to 2022, by gender.

Abbreviations: AOR: age-adjusted odds ratio, CI: confidence intervalNumbers may not add to total due to missing valuesa One year before diagnosis/questionnaire completionb Prior to one year before diagnosis/questionnaire completion; Type 2 diabetesc First degree relatived Age at pancreatic cancer diagnosis for cases and age at questionnaire completion for controlsDescription of study participants, including age-adjusted odds ratio (AOR) estimates for pancreatic cancer risk factors.

ImportanceThe association between the use of hormonal contraceptive and pancreatic cancer among premenopausal women has until now been unclear. This is the first study to investigate the risk of pancreatic cancer in pre-menopausal women.ObjectiveTo determine whether hormonal contraception increases the risk of developing pancreatic cancer in pre-menopausal women.DesignA nationwide prospective cohort study followed all women in Denmark in the age range of 15–49 years without previous cancer or venous thrombosis from 1995 to 2014. The Danish National Prescription Registry provided individually updated exposure information on use of hormonal contraception. The Danish Cancer Registry provided cancer diagnoses, and the Danish National Patient Register containing clinical diagnoses and surgical codes at discharge from public and private hospitals.SettingPopulation-based cohort study.ParticipantsAll women living in Denmark aged 15–49 years at January 1st, 1995, and those subsequently reaching age 15 years up to December 31st, 2014 were eligible for the study.ResultsAmong 1.9 million women who were followed on average for 11.4 years, 235 pancreatic cancers occurred. Compared to never users, ever users of any type of hormonal contraception had a relative risk (RR) of pancreatic cancer of 0.90 (95% confidence interval (CI) 0.68–1.19). No overall association between duration of hormonal contraceptive use and pancreatic cancer risk was found. Neither was long-term use of hormonal contraception associated with pancreas cancer, RR 0.83 (95% CI 0.47–1.50). The risk did not vary between users of combined and progestogen-only products. All models were adjusted for age, completed or ongoing education, polycystic ovary syndrome, endometriosis and among parous women; parity, age at first birth, smoking and body mass index.Conclusions and relevanceCompared to never users the risk of pancreatic cancer is not significantly higher among current and recent users of contemporary hormonal contraception and does not vary between users of combined and progestogen-only products. In conclusion, our study suggests no risk of pancreatic cancer with use of any type of hormonal contraception.

Cancer was responsible for around *** deaths per 100,000 population in the United States in 2023. The death rate for cancer has steadily decreased since the 1990’s, but cancer still remains the second leading cause of death in the United States. The deadliest type of cancer for both men and women is cancer of the lung and bronchus which will account for an estimated ****** deaths among men alone in 2025. Probability of surviving Survival rates for cancer vary significantly depending on the type of cancer. The cancers with the highest rates of survival include cancers of the thyroid, prostate, and testis, with five-year survival rates as high as ** percent for thyroid cancer. The cancers with the lowest five-year survival rates include cancers of the pancreas, liver, and esophagus. Risk factors It is difficult to determine why one person develops cancer while another does not, but certain risk factors have been shown to increase a person’s chance of developing cancer. For example, cigarette smoking has been proven to increase the risk of developing various cancers. In fact, around ** percent of cancers of the lung, bronchus and trachea among adults aged 30 years and older can be attributed to cigarette smoking. Other modifiable risk factors for cancer include being obese, drinking alcohol, and sun exposure.

BackgroundThe 5-year survival rate for pancreatic cancer (PC) is incredibly low, resulting in this often being a fatal disease. Timely and accurate assessment of the survival rate and prognosis of patients with PC is of great significance for the development of new programs for prevention, monitoring, and treatment.MethodsPeriod analysis and further stratified analysis were used to determine the 5-year relative survival rate (RSR) of patients with PC from 2002 to 2016 using the Surveillance, Epidemiology, and End Results (SEER) project database of the National Cancer Institute. Based on this, a generalized linear model was created to predict the survival rate of patients from 2017 to 2021.ResultDuring 2002–2016, the 5-year RSR of patients with PC increased from 7.9 to 23.7%. The generalized linear model predicted that the survival rate had increased to 33.9% during 2017–2021, and hence, it was still unacceptably low. The survival rate of patients aged ≥75 years at diagnosis was the lowest among all age groups and was predicted to be only 21.4% during 2017–2021. Notably, the survival rate of patients with differentiation grade III at diagnosis remains particularly low at 7.6%.ConclusionThe survival rates of patients with PC, although slightly improved, remain extremely low. Timely assessment of the trend of survival rate changes in patients with PC further improves the prognosis of tumor patients and provides data support for relevant medical works to formulate effective tumor prevention and control policies.

This release summarises the survival of adults diagnosed with cancer in England between 2016 and 2020 and followed to 2021, and children diagnosed with cancer in England between 2002 and 2020 and followed to 2021. Adult cancer survival estimates are presented by age, deprivation, gender, stage at diagnosis, and geography.

The Synthetic Pancreatic Cancer Patient Records Dataset has been developed for educational and research purposes to aid in the analysis of clinical biomarkers, demographic indicators, and diagnostic patterns associated with pancreatic cancer. This fully synthetic and anonymised dataset reflects realistic patient cohorts and laboratory data, offering a valuable resource for exploring early detection markers and cancer progression.

Dataset Features

• Patient Cohort: Group label identifying patient subset (e.g., Cohort1).
• Sample Origin: Tissue source of the sample (e.g., LIV = Liver, BPTB = Biopsy via Transbronchial Needle).
• Age: Patient age in years.
• Sex: Biological sex (Male/Female).
• Diagnosis: Coded disease classification (e.g., 2 = Early Cancer, 3 = Advanced Cancer).
• Stage: Cancer stage based on TNM classification (e.g., IIA, IIB, III), available for a subset of patients.
• Benign Sample Diagnosis: Non-malignant diagnosis (e.g., pancreatitis), available for benign cases only.
• Plasma CA19-9: Blood level of the carbohydrate antigen 19-9, a pancreatic cancer biomarker.
• Creatinine: Renal function marker measured in plasma.
• LYVE1: Lymphatic vessel endothelial hyaluronan receptor 1 concentration, a biomarker candidate.
• REG1B: Regenerating islet-derived protein 1-beta concentration.
• TFF1: Trefoil factor 1 concentration, implicated in mucosal healing and carcinogenesis.
• REG1A: Regenerating islet-derived protein 1-alpha concentration.

Distribution

https://storage.googleapis.com/opendatabay_public/d2d8d233-d39c-4a42-80d4-4139c89a2ea7/77dafc0a3021_patient_biomarker_visuals.png" alt="Synthetic Pancreatic Patient Biomarker Visuals.png">

Usage

This dataset can be used for the following applications:

• Cancer Research: Investigate how biomarkers like CA19-9, REG1A/B, and LYVE1 correlate with pancreatic cancer stages and progression.
• Predictive Modeling: Train models to classify disease stage, malignancy, or predict biomarker levels.
• Clinical Insight: Study the diagnostic overlap between benign and malignant samples and identify early diagnostic signals.
• Educational Purposes: Serve as a comprehensive dataset for training in biomedical data analysis, feature engineering, and model evaluation.

Coverage

This dataset is entirely synthetic and anonymised, modelled to reflect the real-world complexity of pancreatic disease diagnosis. It supports both classification and regression tasks and includes numerical, categorical, and partially missing data fields for a realistic preprocessing experience.

License

CC0 (Public Domain)

Who Can Use It

• Medical Researchers and Oncologists: To explore the diagnostic utility of biomarker combinations.
• Data Scientists: To develop and test robust models for early detection and cancer classification.
• Healthcare Educators and Students: As a resource for practical instruction in oncology data science and medical data handling.

Pancreatic Cancer Drug Market Outlook

According to our latest research, the global pancreatic cancer drug market size reached USD 3.2 billion in 2024, demonstrating the increasing focus on advanced oncology treatments. The market is projected to expand at a robust CAGR of 8.4% from 2025 to 2033, reaching an estimated USD 6.5 billion by the end of the forecast period. This growth is propelled by the rising incidence of pancreatic cancer worldwide, significant advancements in drug development, and the increasing adoption of precision medicine. As per our comprehensive analysis, the market is experiencing notable momentum due to the integration of novel therapeutic strategies and the expanding pipeline of targeted and immunotherapeutic agents.

One of the primary growth factors for the pancreatic cancer drug market is the high mortality and poor prognosis associated with pancreatic cancer, which drives urgent demand for more effective and innovative treatments. Pancreatic cancer is often diagnosed at advanced stages due to non-specific symptoms and lack of early detection tools, making it one of the deadliest cancer types. Consequently, pharmaceutical companies and research institutes are intensifying their efforts to develop drugs that can offer better survival outcomes. The growing understanding of the molecular biology of pancreatic cancer has led to the identification of novel targets, fostering the development of targeted therapies and immunotherapies. Regulatory agencies are also expediting the approval of breakthrough therapies, further accelerating market growth.

Another significant growth driver is the increasing investment in research and development by both public and private sectors. Governments across regions are allocating substantial funds to support cancer research, while pharmaceutical giants are entering strategic partnerships and collaborations to expedite drug discovery and development. The emergence of personalized medicine, which tailors treatment based on the genetic profile of patients, is reshaping the landscape of pancreatic cancer therapeutics. Additionally, advancements in diagnostic technologies are enabling earlier detection and more precise patient stratification, thereby improving the efficacy of emerging drug therapies. The market is also benefiting from the growing awareness about cancer symptoms and the importance of early intervention, which is leading to higher diagnosis rates and increased drug consumption.

The expanding geriatric population, particularly in developed economies, is another key factor fueling the growth of the pancreatic cancer drug market. Since the risk of pancreatic cancer increases with age, the rising number of elderly individuals is expected to drive demand for effective treatment options. Furthermore, lifestyle-related risk factors such as smoking, obesity, and diabetes are contributing to the increasing incidence of pancreatic cancer globally. Pharmaceutical companies are responding to this trend by focusing on the development of combination therapies that can target multiple pathways and improve patient outcomes. The growing adoption of combination regimens, supported by favorable reimbursement policies in several countries, is anticipated to further propel market expansion during the forecast period.

From a regional perspective, North America dominates the pancreatic cancer drug market owing to its advanced healthcare infrastructure, high prevalence of pancreatic cancer, and strong presence of leading pharmaceutical companies. Europe follows closely, supported by robust research initiatives and government funding. The Asia Pacific region is emerging as a lucrative market due to rising healthcare investments, increasing awareness, and improving access to advanced therapies. Latin America and the Middle East & Africa are also witnessing gradual growth, driven by improving diagnostic capabilities and expanding healthcare coverage. These regional dynamics underscore the global nature of the market and highlight the need for region-specific strategies to address unique challenges and opportunities.

Pancreatic Cancer Treatment Market Outlook

The global pancreatic cancer treatment market size was valued at approximately USD 2.8 billion in 2023, with projections indicating a steady growth to USD 4.9 billion by 2032, driven by a compound annual growth rate (CAGR) of 6.2%. This growth trajectory can be attributed to several key factors, including significant advancements in treatment methodologies, an increasing prevalence of pancreatic cancer globally, and heightened awareness and early diagnosis, which collectively fuel the demand for effective treatment options. The rise in incidences of pancreatic cancer, now one of the leading causes of cancer-related deaths worldwide, has compelled healthcare providers and pharmaceutical companies to focus extensively on research and development in this field, contributing to market expansion.

One of the primary drivers for the growth of the pancreatic cancer treatment market is the ongoing advancements in medical technology and the development of novel therapeutic approaches. The growing understanding of pancreatic cancer pathophysiology has accelerated the development of targeted therapies and immunotherapies, which are showing promising results in clinical trials. These treatments specifically target cancer cells while minimizing damage to normal cells, thereby enhancing treatment effectiveness and reducing side effects. Innovations in drug delivery systems, such as nanotechnology and personalized medicine approaches, are also contributing to the market's growth by improving the precision and efficacy of existing treatments.

Another significant growth factor is the increased investment in cancer research by governments and private entities across the globe. The substantial funding allocated for cancer research has enabled the expansion of clinical trials and the discovery of new drugs, thus fostering a competitive environment that encourages innovation. Furthermore, public health initiatives aimed at raising awareness about pancreatic cancer, its symptoms, and the importance of early detection have led to a higher number of diagnosed cases. This proactive approach has resulted in a larger patient base seeking treatment, thus propelling market demand. Collaborations between academic institutions, research bodies, and pharmaceutical companies are also pivotal in accelerating the development of effective treatments.

The development and utilization of Pancreatic Cancer Diagnostic Devices play a crucial role in the early detection and management of pancreatic cancer. These devices, which include advanced imaging techniques and biomarker-based tests, are essential for identifying the disease at a stage where treatment can be more effective. As technology evolves, the accuracy and reliability of these diagnostic tools continue to improve, enabling healthcare providers to make more informed decisions regarding patient care. The integration of artificial intelligence and machine learning in diagnostic devices is further enhancing their capability to detect subtle changes indicative of pancreatic cancer, potentially leading to earlier interventions and better patient outcomes. The increasing emphasis on precision diagnostics is expected to drive the demand for these devices, contributing significantly to the overall pancreatic cancer treatment market.

The aging global population is another factor contributing to the market's growth. As the risk of developing pancreatic cancer increases with age, the rising number of elderly individuals necessitates an increase in healthcare services catering to cancer patients. This demographic shift not only increases the incidence of pancreatic cancer but also the demand for comprehensive treatment options. Additionally, lifestyle factors such as smoking, obesity, and diabetes, which are more prevalent in older populations, are known risk factors for pancreatic cancer, further driving the need for advanced treatment solutions.

Regionally, the pancreatic cancer treatment market exhibits varied growth patterns, with North America currently holding the largest market share, followed by Europe and Asia Pacific. The substantial market size in North America is primarily due to the region's advanced healthcare infrastructure, significant R&D investments, and the presence of major pharmaceutical companies. Europe is also a key player, driven by similar factors. The Asia Pacific region, however, is expected to witness the highest growth rate during the forecast period due to the increasing incidence of cancer, improving healthcare infra

Background and objectiveEarly detection methods for pancreatic cancer are lacking. We aimed to develop a prediction model for pancreatic cancer based on changes in health captured by healthcare claims data.MethodsWe conducted a case-control study on 29,646 Medicare-enrolled patients aged 68 years and above with pancreatic ductal adenocarcinoma (PDAC) reported to the Surveillance Epidemiology an End Results (SEER) tumor registries program in 2004–2011 and 88,938 age and sex-matched controls. We developed a prediction model using multivariable logistic regression on Medicare claims for 16 risk factors and pre-diagnostic symptoms of PDAC present within 15 months prior to PDAC diagnosis. Claims within 3 months of PDAC diagnosis were excluded in sensitivity analyses. We evaluated the discriminatory power of the model with the area under the receiver operating curve (AUC) and performed cross-validation by bootstrapping.ResultsThe prediction model on all cases and controls reached AUC of 0.68. Excluding the final 3 months of claims lowered the AUC to 0.58. Among new-onset diabetes patients, the prediction model reached AUC of 0.73, which decreased to 0.63 when claims from the final 3 months were excluded. Performance measures of the prediction models was confirmed by internal validation using the bootstrap method.ConclusionModels based on healthcare claims for clinical risk factors, symptoms and signs of pancreatic cancer are limited in classifying those who go on to diagnosis of pancreatic cancer and those who do not, especially when excluding claims that immediately precede the diagnosis of PDAC.

Within the stroma of pancreatic ductal adenocarcinoma (PDAC), mesenchymal cells differentiate into cancer-associated fibroblast (CAF) subtypes that differentially mediate disease progression. Defining the regulatory mechanism and diversity of CAF subtypes could identify potential therapeutic strategies to harness the tumor suppressive activities of CAFs. To address this, we utilized single-cell RNA sequencing to profile fibroblast activation protein-alpha (FAP) expressing mesenchymal cells in human PDAC. The mesenchymal subpopulations in PDAC reflected mesenchymal cell heterogeneity found in the normal developing pancreas. In addition to characterizing inflammatory CAF (iCAF) and myofibroblastic CAF (myCAF) subpopulations in detail, the analysis uncovered a previously undescribed interferon-response CAF (ifCAF) subtype. Tumor-derived signals induced specific CAF subtypes from pancreatic stellate cells (PSCs) in an organoid-based co-culture model, and time-course experiments revealed regulatory mechanisms that govern subtype formation. STING agonists promoted an ifCAF phenotype in vivo and in vitro. Importantly, induction of an ifCAF phenotype suppressed tumor cell invasiveness and induced an anti-tumor phenotype in tumor-associated neutrophils. Together, this study resolves FAP+ stromal cell heterogeneity in PDAC and identifies an ifCAF subtype that can be induced to suppress pro-tumorigenic features of PDAC (Cumming et al., 2025).

This dataset contains the following data and metadata files:

1. Six pairs of fastq files that contain the actual sequencing data. The total size is 230 GB. Each pair represents a paired-end single-cell RNA sequencing from an individual patient sample. The fastq files are text files with genomic sequence and sequence quality metrics. They are stored as compressed gzip-ed files.
2. A metadata file with sample information. The variables included are: Sample name, sequencing library ID, sequencing depth, sequencing index, number of cells, barcode set, patient pseudo ID (P1-P5), pathologic diagnosis, gender, age, surgical procedure, pathological classification, tumour location, histological status (desmoplasia). This is an Excel file (xlsx).
3. A metadata file with sample information according to the Federated European Genome-Phenome Archive Sweden (FEGA-sweden) template format. This is an Excel file (xlsx).
4. Twelve processed data tables with raw read (UMI) count; Six files for quality filtered cells, and six files with all cells. Each table corresponds to a separate sample. This corresponds to gene expression levels after mapping to the reference genome. The data is stored in MEX format, i.e. three tab-delimited text files in sparse matrix format. The files are compressed with gzip.
5. Two cell annotation tables for the single-cell data. The tables describe read count, gene count, cluster number, and cell type annotation for 30786/26733 single cells from the 6 samples described in the sample information metadata file. The tables are submitted as tab-delimited text files.
6. Two binary files written in R programming language containing an object readable by the Seurat package. The files contain processed data in the form of read count (i.e. gene expression levels) and also as transformed (normalized and scaled) data and analysis results. The files are in RDS format and can be loaded in R.

Hazard ratios and 95% confidence intervals for pancreatic cancer in CanCHEC (1991–2010) by occupational major group (NOC 2011 2 digit codes) adjusted for age, sex, education level, income, immigration status, and province of residence1,2.

BackgroundMany epidemiology studies report that atopic conditions such as allergies are associated with reduced pancreas cancer risk. The reason for this relationship is not yet understood. This is the first study to comprehensively evaluate the association between variants in atopy-related candidate genes and pancreatic cancer risk.MethodsA population-based case-control study of pancreas cancer cases diagnosed during 2011-2012 (via Ontario Cancer Registry), and controls recruited using random digit dialing utilized DNA from 179 cases and 566 controls. Following an exhaustive literature review, SNPs in 180 candidate genes were pre-screened using dbGaP pancreas cancer GWAS data; 147 SNPs in 56 allergy-related immunologic genes were retained and genotyped. Logistic regression was used to estimate age-adjusted odd ratio (AOR) for each variant and false discovery rate was used to adjust Wald p-values for multiple testing. Subsequently, a risk allele score was derived based on statistically significant variants.Results18 SNPs in 14 candidate genes (CSF2, DENND1B, DPP10, FLG, IL13, IL13RA2, LRP1B, NOD1, NPSR1, ORMDL3, RORA, STAT4, TLR6, TRA) were significantly associated with pancreas cancer risk. After adjustment for multiple comparisons, two LRP1B SNPs remained statistically significant; for example, LRP1B rs1449477 (AA vs. CC: AOR=0.37, 95% CI: 0.22-0.62; p (adjusted)=0.04). Furthermore, the risk allele score was associated with a significant reduction in pancreas cancer risk (p=0.0007).ConclusionsPreliminary findings suggest certain atopy-related variants may be associated with pancreas cancer risk. Further studies are needed to replicate this, and to elucidate the biology behind the growing body of epidemiologic evidence suggesting allergies may reduce pancreatic cancer risk.

median and 95% CI was estimated using Kaplan Meier curve by each variable individually.*Hazard Ratio and 95% CI was estimated using multiple Cox regression model adjusted by surgical resection, age group, sex, site of tumor, TNM grade and stage.

ObjectiveCancer of the pancreas is a life-threatening condition and has a high distant metastasis (DM) rate of over 50% at diagnosis. Therefore, this study aimed to determine whether patterns of distant metastases correlated with prognosis in pancreatic ductal adenocarcinoma (PDAC) with metastatic spread, and build a novel nomogram capable of predicting the 6, 12, 18-month survival rate with high accuracy.MethodsWe analyzed data from the Surveillance, Epidemiology, and End Results (SEER) database for cases of PDAC with DM. Kaplan-Meier analysis, log-rank tests and Cox-regression proportional hazards model were used to assess the impact of site and number of DM on the cancer-specific survival (CSS) and over survival (OS). A total of 2709 patients with DM were randomly assigned to the training group and validation group in a 7:3 ratio. A nomogram was constructed by the dependent risk factors which were determined by multivariate Cox-regression analysis. An assessment of the discrimination and ability of the prediction model was made by measuring AUC, C-index, calibration curve and decision curve analysis (DCA). In addition, we collected 98 patients with distant metastases at the time of initial diagnosis from Ningbo University Affiliated LiHuili Hospital to verify the efficacy of the prediction model.ResultsThere was a highest incidence of liver metastases from pancreatic cancer (2387,74.36%), followed by lung (625,19.47%), bone (190,5.92%), and brain (8,0.25%). The prognosis of liver metastases differed from that of lung metastases, and the presence of multiple organ metastases was associated with poorer prognosis. According to univariate and multivariate Cox-regression analyses, seven factors (i.e., diagnosis age, tumor location, grade of tumor differentiation, T-stage, receipt of surgery, receipt of chemotherapy status, presence of multiple organ metastases) were included in our nomogram model. In internal and external validation, the ROC curves, C-index, calibration curves and DCA were calculated, which confirmed that this nomogram can precisely predict prognosis of PDAC with DM.ConclusionMetastatic PDAC patients with liver metastases tended to have a worse prognosis than those with lung metastases. The number of DM had significant effect on the overall survival rate of metastatic PDAC. This study had a high prediction accuracy, which was helpful clinicians to analyze the prognosis of PDAC with DM and implement individualized diagnosis and treatment.

Erlotinib Hydrochloride Tablet Market Outlook

The global market size for Erlotinib Hydrochloride Tablets was significant in 2023, with a projected CAGR of 6.2% from 2024 to 2032, leading to an estimated market size of over USD 2.5 billion by 2032. This growth can be attributed to several factors, including the increasing incidence of cancers such as non-small cell lung cancer (NSCLC) and pancreatic cancer, advancements in cancer treatment methodologies, and an aging population more susceptible to these diseases. Moreover, the rising awareness and early diagnosis of cancer have further propelled the demand for effective treatments like erlotinib hydrochloride tablets.

One of the primary growth factors driving the Erlotinib Hydrochloride Tablet market is the increasing prevalence of non-small cell lung cancer (NSCLC) worldwide. NSCLC accounts for approximately 85% of all lung cancer cases, making it a significant area of focus for pharmaceutical companies and healthcare providers alike. The use of targeted therapies such as erlotinib hydrochloride, which inhibits the epidermal growth factor receptor (EGFR), has shown promising results in improving patient outcomes. This has led to a growing adoption of these tablets as a preferred treatment option, thereby driving market growth.

Another critical growth factor is the advancements in diagnostic technologies, which have enabled the early and accurate detection of cancers. Early diagnosis significantly increases the chances of successful treatment outcomes, leading to a higher demand for effective therapeutic options like erlotinib hydrochloride tablets. Additionally, the growing emphasis on personalized medicine, where treatment plans are tailored to individual patient profiles, has further fueled the demand for targeted therapies. These advancements have collectively contributed to the robust growth of the erlotinib hydrochloride tablet market.

The aging population is also a significant factor contributing to the market's growth. As the global population ages, the incidence of age-related diseases, including various types of cancers, is expected to rise. Older individuals are more susceptible to cancers due to the accumulation of genetic mutations over time and a weakened immune system. This demographic shift has led to an increased demand for effective cancer treatments, including erlotinib hydrochloride tablets, thereby driving market expansion. Furthermore, the increasing healthcare expenditure in many countries is enabling better access to advanced cancer treatments, supporting market growth.

From a regional perspective, North America holds a substantial share of the erlotinib hydrochloride tablet market, driven by a well-established healthcare infrastructure, high awareness levels, and significant healthcare expenditure. The Asia Pacific region is expected to witness the fastest growth during the forecast period, attributed to the rising incidence of cancer, improving healthcare facilities, and increasing government initiatives to combat cancer. Europe also represents a significant market due to the presence of major pharmaceutical companies and advanced healthcare systems. The Middle East & Africa and Latin America, while currently smaller markets, are expected to grow steadily, driven by improving healthcare access and rising cancer awareness programs.

Dosage Form Analysis

The erlotinib hydrochloride tablet market is segmented by dosage form into 25 mg, 100 mg, and 150 mg tablets. Each dosage form caters to different treatment protocols and patient needs, contributing to the overall market dynamics. The 150 mg dosage form is often the standard initial dose for patients with non-small cell lung cancer (NSCLC) and pancreatic cancer, making it a significant segment within the market. This dosage form is favored for its efficacy in achieving therapeutic plasma levels that are necessary for effective cancer treatment. The high demand for the 150 mg dosage form is a key driver of market growth.

The 100 mg dosage form, while less frequently used as an initial treatment dose, plays a crucial role in dose adjustment protocols, particularly in patients who experience adverse side effects at higher doses. This dosage form is often employed in a step-down approach, where the dose is reduced from 150 mg to 100 mg to manage toxicity without compromising the treatment's efficacy. The availability of this intermediate dosage form ensures better patient compliance and continuation of therapy, contributing to its steady demand in the market.

The 25 mg dosage form, although

BackgroundIt remains controversial whether radiotherapy (RT) improves survival in patients with stage IIB/III PDAC. A growing number of studies have found that patients’ age at diagnosis and tumor site not only affect prognosis, but also may lead to different treatment responses. Therefore, the purpose of this study was to verify whether the survival effect of radiotherapy in patients with stage IIB/III PDAC varies across age and tumor site groups.MethodsThe target population was selected from PDAC patients undergone surgery in the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2016. This study performed the Pearson’s chi-square test, Cox regression analysis, Kaplan-Meier (K-M) method, and focused on propensity frequency matching analysis.ResultsNeither neoadjuvant radiotherapy (nRT) nor adjuvant radiotherapy (aRT) patient group had probably improved survival among early-onset patients. For middle-aged patients, nRT seemed to fail to extend overall survival (OS), while aRT might improve the OS. Plus, both nRT and aRT were associated with improved survival in elderly patients. The aRT might be related with survival benefits in patients with pancreatic head cancer, while nRT was not. And RT in patients with PDAC at other sites did not appear to provide a survival benefit.ConclusionCarefully selected data from the SEER database suggested that age and tumor location may be the reference factors to guide the selection of RT for patients with stage IIB/III PDAC. These findings are likely to contribute to the development of personalized treatment for patients with stage IIB/III PDAC.

Endoscopy Ultrasound Market size was valued at USD 1.18 Billion in 2024 and is projected to reach USD 1.87 Billion by 2031, growing at a CAGR of 6.5% from 2024 to 2031.

Global Endoscopy Ultrasound Market Drivers

Growing Prevalence of Gastrointestinal illnesses: The need for endoscopy ultrasound operations for diagnosis and treatment is influenced by the rising incidence of gastrointestinal illnesses, which include malignancies, inflammatory bowel diseases, and gastrointestinal bleeding. Developments in Endoscopic Technologies: By improving the efficacy and precision of diagnostic procedures, ongoing developments in endoscopic ultrasound technologies, such as those involving image resolution enhancements, device miniaturization, and expanded functionality, propel market expansion. Growing Aging Population: As people age, they become more susceptible to a range of illnesses and ailments that may call for tests such as endoscopic ultrasonography. The global trend of population aging is a factor driving the market's expansion. Growing Number of Cancer Diagnoses: Endoscopic ultrasound is essential for the detection and staging of several malignancies, including colorectal, esophageal, and pancreatic cancers. The need for endoscopic ultrasonography operations is driven by the increased global prevalence of cancer cases. Preference for Minimally Invasive Procedures: The adoption of endoscopy ultrasound techniques over traditional surgical approaches is driven by patient preference for minimally invasive procedures that have fewer problems and faster recovery times.

BackgroundPancreatic cancer is one of the most fatal malignancies of the gastrointestinal cancer, with a challenging early diagnosis due to lack of distinctive symptoms and specific biomarkers. The exact etiology of pancreatic cancer is unknown, making the development of reliable biomarkers difficult. The accumulation of patient-derived omics data along with technological advances in artificial intelligence is giving way to a new era in the discovery of suitable biomarkers.MethodsWe performed machine learning (ML)-based modeling using four independent transcriptomic datasets, including GSE16515, GSE62165, GSE71729, and the pancreatic adenocarcinoma (PAC) dataset of the Cancer Genome Atlas. To find candidates for circulating biomarkers, we exported expression profiles of 1,703 genes encoding secretory proteins. Integrating three transcriptomic datasets into either a training or test set, ML-based modeling distinguishing PAC from normal was carried out. Another ML-model classifying long-lived and short-lived patients with PAC was also built to select prognosis-associated features. Finally, circulating level of SCG5 in the plasma was determined from the independent cohort (non-tumor = 25 and pancreatic cancer = 25). We also investigated the impact of SCG5 on adipocyte biology using recombinant protein.ResultsThree distinctive ML-classifiers selected 29-, 64- and 18-featured genes, recognizing the only common gene, SCG5. As per the prediction of ML-models, the SCG5 transcripts was significantly reduced in PAC and decreased further with the progression of the tumor, indicating its potential as a diagnostic as well as prognostic marker for PAC. External validation of SCG5 using plasma samples from patients with PAC confirmed that SCG5 was reduced significantly in patients with PAC when compared to controls. Interestingly, plasma SCG5 levels were correlated with the body mass index and age of donors, implying pancreas-originated SCG5 could regulate energy metabolism systemically. Additionally, analyses using publicly available Genotype-Tissue Expression datasets, including adipose tissue histology and pancreatic SCG5 expression, further validated the association between pancreatic SCG5 expression and the size of subcutaneous adipocytes in humans. However, we could not observe any definite effect of rSCG5 on the cultured adipocyte, in 2D in vitro culture.ConclusionCirculating SCG5, which may be associated with adipopenia, is a promising diagnostic biomarker for PAC.